These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3693582)

  • 21. Indocyanine green disposition in healthy dogs and dogs with mild, moderate, or severe dimethylnitrosamine-induced hepatic disease.
    Boothe DM; Brown SA; Jenkins WL; Green RA; Cullen JM; Corrier DE
    Am J Vet Res; 1992 Mar; 53(3):382-8. PubMed ID: 1595965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative bioavailability of propafenone after administration of a magistral suspension vs. commercial tablets in healthy volunteers.
    Juárez Olguín H; Flores Pérez C; Ramírez Mendiola B; Barranco Garduño L; Sandoval Ramírez E; Flores Pérez J
    Arzneimittelforschung; 2009; 59(3):117-20. PubMed ID: 19402341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolism and disposition of buspirone.
    Gammans RE; Mayol RF; LaBudde JA
    Am J Med; 1986 Mar; 80(3B):41-51. PubMed ID: 3515929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
    Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
    Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the pharmacodynamic effects of intravenous and oral propafenone.
    Haefeli EW; Vozeh S; Ha HR; Follath F
    Clin Pharmacol Ther; 1990 Sep; 48(3):245-54. PubMed ID: 2401123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model.
    Stoeckel K; Koup JR
    Am J Med; 1984 Oct; 77(4C):26-32. PubMed ID: 6093514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Indocyanine green intrinsic hepatic clearance as a prognostic index of survival in patients with cirrhosis.
    Merkel C; Bolognesi M; Finucci GF; Angeli P; Caregaro L; Rondana M; Gatta A
    J Hepatol; 1989 Jul; 9(1):16-22. PubMed ID: 2768794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Propafenone disposition in renal insufficiency and renal failure.
    Burgess E; Duff H; Wilkes P
    J Clin Pharmacol; 1989 Feb; 29(2):112-3. PubMed ID: 2715367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone.
    Dilger K; Hofmann U; Klotz U
    Clin Pharmacol Ther; 2000 May; 67(5):512-20. PubMed ID: 10824630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
    Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Significance of the degree of oxidative hepatic metabolism in conditioning the pharmacokinetics and the pharmacodynamics of propafenone].
    Boriani G; Capucci A; Strocchi E; Marchesini B; Baroni M; Frabetti L; Ambrosioni E; Magnani B
    G Ital Cardiol; 1991 May; 21(5):517-26. PubMed ID: 1936756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Propafenone disposition kinetics in cardiac arrhythmia.
    Connolly S; Lebsack C; Winkle RA; Harrison DC; Kates RE
    Clin Pharmacol Ther; 1984 Aug; 36(2):163-8. PubMed ID: 6744775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics in liver disease.
    Breimer DD
    Pharm Weekbl Sci; 1987 Apr; 9(2):79-84. PubMed ID: 3295764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
    Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J
    Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of conivaptan use in patients with severe hepatic impairment.
    Marbury T; Fox J; Kaelin B; Pavliv L
    Drug Des Devel Ther; 2017; 11():373-382. PubMed ID: 28243060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of different positive end-expiratory pressure values on liver function and indocyanine green clearance test in liver transplantation donors: a prospective, randomized, double-blind study.
    Bıcakcıoglu M; Aydogan MS; Sayan H; Toprak HI; Isik B; Yılmaz S; Yologlu S
    Transplant Proc; 2015 May; 47(4):1190-3. PubMed ID: 26036551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatic disease and drug pharmacokinetics.
    Williams RL; Mamelok RD
    Clin Pharmacokinet; 1980; 5(6):528-47. PubMed ID: 7002418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical pharmacokinetics of propafenone.
    Hii JT; Duff HJ; Burgess ED
    Clin Pharmacokinet; 1991 Jul; 21(1):1-10. PubMed ID: 1914339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.
    Lavene D; Weiss YA; Safar ME; Loria Y; Agorus N; Georges D; Milliez PL
    J Clin Pharmacol; 1977; 17(8-9):501-8. PubMed ID: 893736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Propafenone Research Group.
    Zoble RG; Kirsten EB; Brewington J
    Clin Pharmacol Ther; 1989 May; 45(5):535-41. PubMed ID: 2721109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.